Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Expands bioprocessing footprint across Asia
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Subscribe To Our Newsletter & Stay Updated